135 related articles for article (PubMed ID: 15157985)
21. The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes.
Bour S; Iglesias-Osma MC; Marti L; Duro P; Garcia-Barrado MJ; Pastor MF; Prévot D; Visentin V; Valet P; Moratinos J; Carpéné C
Eur J Pharmacol; 2006 Dec; 552(1-3):20-30. PubMed ID: 17056035
[TBL] [Abstract][Full Text] [Related]
22. The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat striatum in vivo.
Sastre-Coll A; Esteban S; Miralles A; Zanetti R; García-Sevilla JA
Neurosci Lett; 2001 Mar; 301(1):29-32. PubMed ID: 11239709
[TBL] [Abstract][Full Text] [Related]
23. Isothiocyanatobenzyl imidazoline is an alkylating agent for I2-imidazoline binding sites in rat and rabbit tissues.
Boronat MA; Olmos G; Miller DD; Patil PN; García-Sevilla JA
Naunyn Schmiedebergs Arch Pharmacol; 1998 Mar; 357(3):351-5. PubMed ID: 9550309
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine.
MacInnes N; Handley SL
Br J Pharmacol; 2002 Mar; 135(5):1227-34. PubMed ID: 11877331
[TBL] [Abstract][Full Text] [Related]
25. Novel imidazoline compounds as partial or full agonists of D2-like dopamine receptors inspired by I2-imidazoline binding sites ligand 2-BFI.
Giorgioni G; Ambrosini D; Vesprini C; Hudson A; Nasuti C; Di Stefano A; Sozio P; Ciampi O; Costa B; Martini C; Carrieri A; Carbonara G; Enzensperger C; Pigini M
Bioorg Med Chem; 2010 Oct; 18(19):7085-91. PubMed ID: 20801048
[TBL] [Abstract][Full Text] [Related]
26. Role of intracellular Ca
Siemian JN; Qiu Y; Zhang Y; Li JX
Psychopharmacology (Berl); 2017 Nov; 234(22):3299-3307. PubMed ID: 28825118
[TBL] [Abstract][Full Text] [Related]
27. Attenuation of acute and chronic effects of morphine by the imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline in rat locus coeruleus neurons.
Ruiz-Durántez E; Torrecilla M; Pineda J; Ugedo L
Br J Pharmacol; 2003 Feb; 138(3):494-500. PubMed ID: 12569074
[TBL] [Abstract][Full Text] [Related]
28. Binding of the imidazoline ligand 3H-2-benzofuranyl-2-imidazoline (BFI) to human brain and platelets. Potentiation by tranylcypromine and role of MAO isoforms.
Steinberg MI; Wiest SA; Pickard RT; Chen K; Shih JC
Ann N Y Acad Sci; 1999 Jun; 881():193-8. PubMed ID: 10415915
[No Abstract] [Full Text] [Related]
29. Potential serotonergic and noradrenergic involvement in the discriminative stimulus effects of the selective imidazoline I2-site ligand 2-BFI.
MacInnes N; Handley SL
Pharmacol Biochem Behav; 2003 May; 75(2):427-33. PubMed ID: 12873635
[TBL] [Abstract][Full Text] [Related]
30. Identification of ligands selective for central I2-imidazoline binding sites.
Hudson AL; Chapleo CB; Lewis JW; Husbands S; Grivas K; Mallard NJ; Nutt DJ
Neurochem Int; 1997 Jan; 30(1):47-53. PubMed ID: 9116587
[TBL] [Abstract][Full Text] [Related]
31. In vivo estimation of imidazoline(2) binding site turnover.
Paterson LM; Robinson ES; Nutt DJ; Hudson AL
Ann N Y Acad Sci; 2003 Dec; 1009():367-70. PubMed ID: 15028614
[TBL] [Abstract][Full Text] [Related]
32. Brain protection conferred by long-term administration of 2-(2-benzofuranyl)-2-imidazoline against experimental autoimmune encephalomyelitis.
Zhu YB; Xia NG; Zhang YT; Wang XS; Liang SS; Yin WY; Xu HQ; Hou ST; Zheng RY
Neurochem Res; 2015 Mar; 40(3):572-8. PubMed ID: 25522738
[TBL] [Abstract][Full Text] [Related]
33. Characterization of [(3)H]idazoxan binding sites on human platelets.
Ruiz J; Barinagarrementeria G; Martín-Gómez JI; Callado LF; Meana JJ
Platelets; 2002 Jun; 13(4):241-6. PubMed ID: 12189026
[TBL] [Abstract][Full Text] [Related]
34. Testing conception of engagement of imidazoline receptors in imidazoline drugs effects on isolated rat heart atria.
Radwanska A; Dlugokecka J; Wasilewski R; Kaliszan R
J Physiol Pharmacol; 2009 Mar; 60(1):131-42. PubMed ID: 19439815
[TBL] [Abstract][Full Text] [Related]
35. Effects of the imidazoline I2 receptor agonist 2-BFI on the development of tolerance to and behavioural/physical dependence on morphine in rats.
Thorn DA; Zhang Y; Li JX
Br J Pharmacol; 2016 Apr; 173(8):1363-72. PubMed ID: 26776953
[TBL] [Abstract][Full Text] [Related]
36. The imidazoline I
Siemian JN; Woodhouse K; Liu DH; Zhang Y; Li JX
Psychopharmacology (Berl); 2024 Mar; 241(3):479-487. PubMed ID: 38159161
[TBL] [Abstract][Full Text] [Related]
37. The imidazoline I
Siemian JN; LaMacchia ZM; Spreuer V; Tian J; Ignatowski TA; Paez PM; Zhang Y; Li JX
Biochem Pharmacol; 2018 Jul; 153():260-268. PubMed ID: 29366977
[TBL] [Abstract][Full Text] [Related]
38. Antinociceptive effects of imidazoline I2 receptor agonists in the formalin test in rats.
Thorn DA; Qiu Y; Jia S; Zhang Y; Li JX
Behav Pharmacol; 2016 Jun; 27(4):377-83. PubMed ID: 26599907
[TBL] [Abstract][Full Text] [Related]
39. Neuroanatomical characterization of imidazoline I
Siemian JN; Jia S; Liu JF; Zhang Y; Li JX
Eur J Neurosci; 2018 May; 47(9):1087-1095. PubMed ID: 29514408
[TBL] [Abstract][Full Text] [Related]
40. Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding.
Levin ED; Tizabi Y; Rezvani AH; Caldwell DP; Petro A; Getachew B
Brain Res; 2005 Apr; 1041(2):132-42. PubMed ID: 15829222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
